ONCOLOGY TRAINING PROGRAMS FOR SITE STAFF CONDUCTING CLINICAL RESEARCH

These clinical research training courses have been created by the Clinical Imaging Team at Merck Research Laboratories to support understanding of response evaluation criteria isolid tumors (RECIST1) and response evaluation criteria in clinical trials with immunotherapies (iRECIST2):

Recognition or acceptance of course completion may vary by clinical trial sponsor.

 

1 Eisenhauer EA 2009 ‘New response evaluation criteria in solid tumors: Revised RECIST guideline (version 1.1)’ EJC  45: 228-247

2 Seymour L 2017 ‘iRECIST: guidelines for response criteria for use in trials testing immunotherapies’, Lancet Oncology 18: e143-52).

Please complete the form below for access to RECIST Training Modules

Merck iRecist Modules
SCRS does not provide contact information to other parties. By continuing, you agree that SCRS may contact you with promotional or informational content via email, and you may opt-out at any time. *

RECIST 1.1

The Response Evaluation Criteria In Solid Tumors (RECIST) v1.1 is the most commonly used method for evaluating changes in tumor burden over time during an oncology clinical trial, and deciding whether the trial participant showed a favorable treatment response or treatment failure. It is used in most malignancies other than hematological malignancies, and has been the basis for numerous regulatory approvals. This course will explain the basic concepts and the detailed steps involved in turning assessments of medical imaging scans into clinical trial endpoints.

RECIST 1.1 for Site Personnel

iRECIST

This modification of the Response Evaluation Criteria In Solid Tumors (RECIST), published in 2017, is tailored to clinical trials involving cancer immunotherapy, which sometimes causes atypical patterns of treatment response not accounted for by traditional RECIST criteria. This course starts with an assumption that the student already has a strong foundation in RECIST 1.1, and discusses the background for the modified criteria and the process of applying them to evaluating tumor changes in trial participants who appear to exhibit radiographic disease progression.

 iRECIST for Site Personnel Modified for Immunotherapy